Breaking News

Financial Report: PAREXEL

August 7, 2014

Revenues up 11% in the quarter

PAREXEL

4Q Revenues: $585.1 million (+11%)

4Q Earnings: $40.1 million (+34%)

FY Revenues: $2.3 billion (+14%)

FY Earnings: $129.1 million (+34%)

Comments: Consolidated service revenue increased 10% in the quarter to $510.6 million, with $385.6 million in Clinical Research Services (CRS), $55.2 million in PAREXEL Consulting (PC), and $69.8 million in PAREXEL Informatics (PI). For the year consolidated service revenue was up 12% to $1.9 billion, with $1.5 billion in CRS, $216.2 million in PC, and $267.9 million in PAREXEL Informatics, Inc.The recent acquisition of the HERON Group contributed approximately $3.8 million in the quarter, and contributed $2.2 million for the fiscal year. Backlog at the end of June 2014 was $5.0 billion, up 9% for the year.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks